Icon Plc (NASDAQ:ICLR) – Equities research analysts at KeyCorp reduced their FY2019 earnings per share (EPS) estimates for shares of Icon in a report issued on Thursday. KeyCorp analyst D. Hooker now anticipates that the medical research company will post earnings of $6.97 per share for the year, down from their previous estimate of $6.98. KeyCorp has a “Buy” rating and a $130.00 price target on the stock.
Other equities research analysts also recently issued research reports about the company. Zacks Investment Research downgraded Icon from a “buy” rating to a “hold” rating in a research report on Wednesday, November 1st. Mizuho restated a “neutral” rating and set a $114.00 target price (up previously from $109.00) on shares of Icon in a research report on Thursday, February 15th. BidaskClub upgraded Icon from a “strong sell” rating to a “sell” rating in a research report on Friday, February 9th. Credit Suisse Group upgraded Icon to a “buy” rating and set a $131.00 target price on the stock in a research report on Friday, February 16th. Finally, Barclays increased their target price on Icon from $108.00 to $120.00 and gave the stock an “equal weight” rating in a research report on Friday, October 27th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $126.00.
Icon (ICLR) traded up $0.05 during trading on Monday, reaching $115.06. The company had a trading volume of 363,300 shares, compared to its average volume of 346,971. The stock has a market capitalization of $6,228.02, a P/E ratio of 22.40, a price-to-earnings-growth ratio of 1.62 and a beta of 0.48. Icon has a fifty-two week low of $76.46 and a fifty-two week high of $124.48. The company has a current ratio of 1.90, a quick ratio of 1.90 and a debt-to-equity ratio of 0.31.
Icon (NASDAQ:ICLR) last posted its quarterly earnings data on Thursday, February 15th. The medical research company reported $1.43 EPS for the quarter, beating the consensus estimate of $1.41 by $0.02. Icon had a return on equity of 28.60% and a net margin of 16.01%. The business had revenue of $455.10 million for the quarter, compared to the consensus estimate of $455.66 million. During the same quarter in the prior year, the business earned $1.33 earnings per share. Icon’s revenue for the quarter was up 4.6% on a year-over-year basis.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in ICLR. SPF Beheer BV bought a new position in Icon in the fourth quarter valued at $92,565,000. Renaissance Technologies LLC increased its stake in Icon by 37.5% in the fourth quarter. Renaissance Technologies LLC now owns 1,817,307 shares of the medical research company’s stock valued at $203,811,000 after acquiring an additional 495,247 shares during the last quarter. Principal Financial Group Inc. increased its stake in Icon by 71.5% in the third quarter. Principal Financial Group Inc. now owns 768,471 shares of the medical research company’s stock valued at $87,513,000 after acquiring an additional 320,356 shares during the last quarter. WCM Investment Management CA increased its stake in Icon by 5.8% in the fourth quarter. WCM Investment Management CA now owns 4,281,211 shares of the medical research company’s stock valued at $480,138,000 after acquiring an additional 233,990 shares during the last quarter. Finally, Ameriprise Financial Inc. increased its stake in Icon by 530.2% in the third quarter. Ameriprise Financial Inc. now owns 248,202 shares of the medical research company’s stock valued at $28,265,000 after acquiring an additional 208,816 shares during the last quarter. 89.18% of the stock is currently owned by institutional investors and hedge funds.
TRADEMARK VIOLATION NOTICE: This piece was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece on another publication, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The legal version of this piece can be viewed at https://www.dispatchtribunal.com/2018/02/21/keycorp-comments-on-icon-plcs-fy2019-earnings-iclr.html.
Icon Company Profile
ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies.
Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.